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Abstract
Background: Overactive bladder (OAB) syndrome is a symptom complex affecting 12–14% of the UK adult female
population. Symptoms include urinary urgency, with or without urgency incontinence, increased daytime urinary
frequency and nocturia. OAB has a negative impact on women’s social, physical, and psychological wellbeing. Initial
treatment includes lifestyle modifications, bladder retraining, pelvic floor exercises and pharmacological therapy.
However, these measures are unsuccessful in 25–40% of women (refractory OAB). Before considering invasive
treatments, such as Botulinum toxin injection or sacral neuromodulation, most guidelines recommend urodynamics
to confirm diagnosis of detrusor overactivity (DO). However, urodynamics may fail to show evidence of DO in up to
45% of cases, hence the need to evaluate its effectiveness and cost-effectiveness. FUTURE (Female Urgency, Trial of
Urodynamics as Routine Evaluation) aims to test the hypothesis that, in women with refractory OAB, urodynamics
and comprehensive clinical assessment is associated with superior patient-reported outcomes following treatment
and is more cost-effective, compared to comprehensive clinical assessment only.
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Methods: FUTURE is a pragmatic, multi-centre, superiority randomised controlled trial. Women aged ≥ 18 years
with refractory OAB or urgency predominant mixed urinary incontinence, and who have failed/not tolerated
conservative and medical treatment, are considered for trial entry. We aim to recruit 1096 women from
approximately 60 secondary/tertiary care hospitals across the UK. All consenting women will complete
questionnaires at baseline, 3 months, 6 months and 15 months post-randomisation. The primary outcome is
participant-reported success at 15 months post-randomisation measured using the Patient Global Impression of
Improvement. The primary economic outcome is incremental cost per quality-adjusted life year gained at 15
months. The secondary outcomes include adverse events, impact on other urinary symptoms and health-related
quality of life. Qualitative interviews with participants and clinicians and a health economic evaluation will also be
conducted. The statistical analysis of the primary outcome will be by intention-to-treat. Results will be presented as
estimates and 95% CIs.
Discussion: The FUTURE study will inform patients, clinicians and policy makers whether routine urodynamics
improves treatment outcomes in women with refractory OAB and whether it is cost-effective.
Trial registration: ISRCTN63268739. Registered on 14 September 2017.
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Introduction
Background and rationale {6a}
Overactive bladder (OAB) syndrome has been defined
by the International Continence Society (ICS) as urinary
urgency, with or without urgency urinary incontinence,
usually with increased daytime frequency and nocturia,
in the absence of any other pathology [1].
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The Leicestershire MRC (Medical Research Council)
Incontinence Study showed a 21% overall prevalence of
OAB in women aged ≥ 40 years in the United Kingdom
(UK); UUI and mixed urinary incontinence (MUI)
represented 11% and 36% of these women respectively
[2]. The Epidemiology of Lower Urinary Tract
Symptoms (EpiLUTS) study reported relatively higher
UUI prevalence rates of 13.3% for men and 30.3% for
women in the USA [3]. In 2016, Komeso reported a
large epidemiological study showing that the prevalence
of urinary incontinence (UI) increases with age; this was
most apparent for UUI and MUI: the odds of
occurrence of UUI were 2- and 9-fold increased in the
7th and 10th decades, compared with the 6th decade
(OR 2.18; 95%CI = 1.5–3.15 and OR = 9.19; 95%CI =
5.56–15.20) respectively [4]. The prevalence of MUI also
significantly increased in the 8th to10th decades (both P
≤ 0.005), but interestingly, the prevalence of stress urin-
ary incontinence (SUI) did not seem to increase with age
in this study. Similar results were shown by the EPIN-
CONT study of 28,000 women [5]. The EPIC prevalence
data estimates that the worldwide number of adults aged
≥ 20 years with UUI or MUI was 103 million in 2008,
with projected increase to 127 million in 2018 [6].
Therefore, the prevalence of OAB/MUI is likely to in-
crease in the years to come, especially given the ageing
population in the UK.
OAB and UUI have been shown to have a negative
impact on a woman’s social, physical and psychological
wellbeing, leading to embarrassment, low self-esteem
and negative effects on the productivity of working
women. In extreme cases, women reported avoiding em-
ployment because of fear of embarrassing situations [2,
7]; 60% avoided going away from home; and 50% re-
ported avoidance of sexual activity [8]. This debilitating
social problem has significant cost implications to the
health resources in the UK. The total annual cost to the
National Health Service (NHS) is £301 million or 0.3%
of the total NHS budget in 2009 [9]. Costs borne by
women and their families (e.g. for containment prod-
ucts) were £230 million [10]. Health-related costs for
management of OAB and UUI was estimated at approxi-
mately €7.0 billion in 2005 across 6 countries: Canada,
Germany, Italy, Spain, Sweden and the UK [6].
The National Institute for Health and Care Excellence
(NICE) shows the standard benchmark rate for a referral
into a UI service for UK women is 0.8% (800 per
100,000 adult female/ year) [11]. In women diagnosed
with OAB, the NICE Guideline CG171 recommends
initial conservative treatment which includes the
following: lifestyle modifications, bladder training and
pelvic floor exercise and pharmacological therapy
(anticholinergics and/or beta-3 agonist). However, these
measures are unsuccessful for approximately 25–40% of
women (i.e. refractory OAB) [12]. For these women,
NICE recommends “urodynamics” investigation to con-
firm the diagnosis of detrusor overactivity (DO) before
proceeding to invasive treatments such as Botulinum
toxin-A injection (BoNT-A) or sacral neuro-modulation
(SNM) [11]. NICE CG171 was the relevant guideline at
time of the FUTURE study planning; however, the rec-
ommendation has not changed in the updated NICE
NG123 [13].
Invasive urodynamics is a diagnostic test that involves
the insertion of one to two catheters into the bladder
and another one into the vagina or the rectum. The
rationale for urodynamics is to reproduce the women’s
symptoms and to identify the underlying pathology.
During bladder filling, DO may be seen; these are
uninhibited bladder contractions, which hinder effective
urine storage, and are frequently associated with urgency
and/or UUI. Urodynamic stress incontinence (USI) may
also be seen, and if USI and DO incontinence (DOI) are
both present, the woman is diagnosed with MUI.
Urodynamics can also identify other pathology, for
example bladder outlet obstruction or detrusor
underactivity, which may influence the choice of
therapy.
Although urodynamics is currently the recommended
investigation in the NICE guidelines for the assessment
of women with refractory OAB and/or MUI [11, 13], the
clinical and cost-effectiveness of urodynamics have not
been demonstrated in well designed, adequately powered
clinical trials. Interestingly, some of the current evidence
on the value of urodynamics in these women suggests
little impact, if any, on the post-treatment patient-
reported outcomes [14].
Invasive treatments for refractory OAB
Current guidelines recommend BoNT-A or SNM as the
treatments for women with refractory OAB following
failure of conservative and medical treatment [11, 13].
BoNT-A treatment is an injection into the bladder
wall using a cystoscope (rigid or flexible), either under
general or more commonly local anaesthesia. The
treatment, if successful, is usually repeated every 6 to 12
months.
In women with refractory OAB and associated DO on
urodynamics, Brubaker et al. showed that approximately
60% who received BoNT-A had a positive clinical re-
sponse on the Patient Global Impression of Improve-
ment scale (PGI-I) [15]. Secondary analyses from two
recent randomised controlled trials (RCTs) of BoNT-A
versus placebo suggested that successful treatment out-
comes did not appear to be related to the pre-operative
urodynamics diagnosis of DO [14, 16]. Chapple et al., in
a double-blind, placebo-controlled RCT, showed that
BoNT-A significantly improves all symptoms of
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refractory OAB and quality of life (QoL); there was no
impact of the pre-operative diagnosis of DO on the
treatment outcomes [16]. Similarly, Rovner et al. in a
placebo-controlled RCT showed 57% of the patients
were satisfied compared to 19% placebo at 3 months fol-
lowing BoNT-A treatment, irrespective of the presence
of DO on urodynamics [14]. BoNT-A is now licensed in
the UK for treatment of idiopathic refractory OAB
symptoms (with symptoms of urinary incontinence, ur-
gency and frequency) without the need for pre-operative
urodynamics [17].
In a recent observational study embedded within the
BUS RCT, 666 women with non-refractory OAB under-
went urodynamics; the results suggested that clinicians
and patients appeared to be guided in part by the uro-
dynamics diagnosis in selecting treatment options [18].
Several confounding influences were identified, such as
natural fluctuation of disease state, regression to the
mean and Hawthorne effects. The economic modelling
within the BUS study suggested that urodynamics can
be a cost-effective diagnostic strategy for women with
predominant symptoms of OAB [18]. However, this was
based on fewer women undergoing invasive treatment in
the urodynamics group. The authors reported significant
cost savings in the urodynamics group associated with a
small reduction in clinical effectiveness. It is important
to highlight that the BUS study assessed a different co-
hort of women with significantly milder OAB symptoms
and therefore the results could not be generalised to
women with refractory OAB.
The principle of SNM is that electrical stimulation of
the sacral reflex pathway will inhibit the reflex behaviour
of the bladder. SNM is a two-stage procedure; stage one
is a SNM test using either a temporary or permanent
lead, connected to an external stimulator, while the sec-
ond stage involves the placement of a subcutaneous im-
plantable pulse generator (permanent implant). If a
patient reports at least 50% improvement of the refrac-
tory OAB symptoms during the test phase, as recorded
in the bladder diaries, they are offered the permanent
implant. SNM has the unique advantage that patient
outcomes are assessed before a commitment is made to
the permanent procedure.
Three RCTs comparing SNM to placebo showed that
52% of patients were dry at 18 months and a further 24%
reported at least 50% reduction in leakage episodes (n =
58); at 3 years, 46% were dry and 13% improved [19–21].
In one RCT, patients with urgency and frequency
showed improvements in several SF-36 domains in the
active treatment group (n = 51; 90% women) at 6
months follow-up [21]. NICE concluded that following
SNM, up to two-thirds of patients achieve continence or
substantial improvement in symptoms, with the benefi-
cial effects lasting for up to 3–5 years after implantation
[11]. Around one third of patients may require reopera-
tion, most often due to pain at the implant site, infec-
tion, or the need for adjustment and modification of the
lead system. Interestingly, while urodynamics investiga-
tion is considered a standard practice prior to SNM
treatment in NICE CG171 and NG123, confirmation of
DO is not [11, 13]. One recent observational study re-
ported that pre-operative diagnosis of DO was not a pre-
requisite selection criterion for SNM [22].
Sequence of treatment in women with refractory OAB
The best sequence of interventions for women with
refractory OAB is not known.
In 2013, NICE CG171 included a heath economic
evaluation which suggested that BoNT-A was a cost-
effective intervention, in comparison with either no
active treatment or SNM and NICE recommended of-
fering BoNT-A as first intervention to women with
refractory OAB and DO [11]. They recommended
SNM for women unable to catheterise or who have a
cultural or ethical objection to catheterisation (slightly
amended in NG123 to women unprepared to accept
risks of clean intermittent self-catheterisation (CISC)
with BoNT-A), or those with persistent symptoms fol-
lowing BoNT-A treatment) [11, 13].
Interestingly, evidence from one recent study
highlighted that 61% of women receiving BoNT-A dis-
continued their treatment at 3 years while 64% discon-
tinued at 5 years [23]. Most recently, Marcelissen et al.
showed that only 30% of their patients initiated on
BoNT-A treatment were still on treatment at minimum
follow-up of 5 years; the majority of patients who discon-
tinued treatment (98%) did so after the 1st or 2nd injec-
tion [24]. In an economic model comparing SNM with
BoNT-A over a 5-year period with a societal perspective,
Leong et al. reported a greater gain in quality-adjusted
life years (QALY) and a greater associated cost savings
when patients were initiated on SNM treatment [25]. As
the QALY gain from BoNT-A injection was lower due
to the loss of effect with reinjections over time, SNM be-
came cost-effective after 5 years compared with BoNT-
A, with an incremental cost-effectiveness ratio of 27,991
Euros, within the accepted NICE threshold of £20,000 to
£30,000.
Accordingly, UK practice varies and usually relies on
treatment options available locally within the units. Our
brief survey of the potential collaborating centres for the
FUTURE study suggests a considerable number of units
and surgeons offer BoNT-A treatment for women with
refractory OAB with and without urodynamics evidence
of DO. In addition, in tertiary units where SNM may be
readily available, surgeons tend to offer women with
confirmed DO the choice between BoNT-A or SNM
after discussion by the local multidisciplinary team
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(MDT). Some surgeons indicated that they favour SNM
in younger patients and/or those with associated voiding
dysfunction or faecal incontinence.
In summary, the current evidence highlights the
uncertainties and the need for a robust RCT to address
this important research question which was prioritised
by the NICE guideline CG171 research
recommendations: “Further research is needed to answer
the question of whether the use of invasive urodynamics,
prior to initial or subsequent treatments, affects the
outcomes and cost-effectiveness of interventions in
women with UI or OAB” [11].
Rationale for the trial
NICE recommends urodynamics investigation to
confirm the diagnosis of DO in women with refractory
OAB before proceeding to invasive treatment [11].
For clinicians, urodynamics is traditionally considered
to inform the counselling of women on the chances of
success of subsequent treatments. However, in women
with refractory OAB, urodynamics fails to show
evidence of DO in up to 45% [26]. The accuracy of
urodynamics relies on well-calibrated equipment, experi-
ence of investigators and their interpretation of a num-
ber of subjective parameters. Standardisation of
urodynamics is difficult and is influenced by wide vari-
ation in staff practice and equipment used [27]. These
factors raise a valid debate on the clinical and cost-
effectiveness of urodynamics and whether it actually
improves the outcomes of subsequent treatments com-
pared to treatment guided by comprehensive clinical as-
sessment only.
From the patients’ perspective, many describe
urodynamics as an invasive and embarrassing
investigation and associated with an element of
emotional distress [28, 29]. Urodynamics is also
associated with a risk of discomfort and urinary tract
infection [18]. However, the majority of women find it
acceptable if it will improve their outcomes post-
treatment [18, 30–32]. Unfortunately, the urodynamics
test may not replicate the patients’ symptoms in their
day to day lives which questions the validity of the treat-
ment options offered based on its results.
For policy makers, inevitably urodynamics is costly to
the NHS, including purchase of equipment and
disposables, and the need for specialist staff. The
urodynamics tariff was £256/patient at the time of the
development of the study protocol. Policy makers are
faced with the current pressure on health resources in
the UK; therefore, there is a pressing need to direct
resources towards evidence-based interventions that are
proven to positively improve treatment outcomes.
Urodynamics is one such test that has been embedded
in clinical practice without robust evidence of its clinical
or cost-effectiveness. Current evidence shows uro-
dynamics to have no impact on the patient-reported out-
comes following conservative treatment of UI [33] and
for those undergoing surgical treatment for symptoms of
pure SUI [34]. Accordingly, NICE CG171 has prioritised
research to assess the clinical and cost-effectiveness of
urodynamics in treatment of refractory OAB [11].
The outcome of the FUTURE study would inform
patients, clinicians and policy makers whether routine
urodynamics investigation improves the treatment




Does routine urodynamics investigation in addition to
comprehensive clinical assessment improve patient-
reported outcomes following treatment, compared to
comprehensive clinical assessment only, in women with
refractory OAB symptoms, and is it cost-effective?
Hypothesis
In women with refractory OAB, urodynamics and
comprehensive clinical assessment is associated with
superior patient-reported outcomes following treatment
and is more cost-effective, compared to comprehensive
clinical assessment only.
The primary objectives are to:
1. Evaluate whether routine urodynamics investigation
and comprehensive clinical assessment significantly
improves patient-reported success rates following treat-
ment, compared to comprehensive clinical assessment
only;
2. Assess the cost-effectiveness of routine urodynamics
investigation and comprehensive clinical assessment,
compared to comprehensive clinical assessment only.
Secondary objectives are to:
1. Assess the above outcomes in pre-specified sub-
groups of women: OAB and urgency predominant
MUI.
2. Explore the clinicians’ attitudes towards
urodynamics investigation and its influence on
surgical decision-making;
3. Explore the participants attitudes and experience in
both pathways;
4. Explore the clinical and cost-effectiveness of the dif-
ferent sequence of treatments for refractory OAB.
Trial design {8}
This is a pragmatic, multi-centre, superiority RCT com-
paring the effectiveness and cost-effectiveness of routine
urodynamics investigation and comprehensive clinical
assessment versus comprehensive clinical assessment
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only in the management of women with refractory OAB
symptoms (Fig. 1). An internal pilot study with stop/
go criteria is embedded within the RCT to establish
whether the projected recruitment rate is
achievable.
The trial design includes an economic evaluation from
a National Health Service (NHS) perspective, using both
a within trial timeframe and a modelled patient lifetime
timeframe. Unit costs will be taken from standard
sources (NHS Reference Costs, British National
Formulary and ‘Unit Costs of Health and Social Care’).
Costs and outcomes are discounted at 3.5%. An
embedded qualitative component is also included in the
trial design to evaluate the patients’ attitudes to, and
experiences of, invasive urodynamic testing, and also
clinicians’ views on the influence of urodynamics on
decision-making.
Methods: participants, interventions and
outcomes
Study setting {9}
We are recruiting 1096 women aged ≥ 18 years, with
refractory OAB symptoms, across approximately 60
secondary and tertiary care hospitals in the UK.
Eligibility criteria {10}
Women aged ≥ 18 years with refractory OAB or urgency
predominant MUI (i.e. in whom OAB are their most
bothersome symptoms), and
Fig. 1 Flow diagram illustrating the participants journey through the FUTURE trial
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 Have failed conservative management (as per NICE
guideline, e.g. pelvic floor muscle training/ bladder
retraining) and
 Have failed or have not tolerated pharmacological
treatment (at least 2 different drugs) unless
contraindicated and
 Are being considered for invasive treatment.
The exclusion criteria are:
 Predominant SUI symptoms;
 Previous urodynamics in the last 12 months;
 Current pelvic malignancy or clinically significant
pelvic mass;
 Bladder pain syndrome;
 Neurogenic bladder (e.g. Parkinson’s disease, spinal
injuries);
 Urogenital fistulae;
 Previous treatment with BoNT-A/SNM for UI;
 Previous pelvic radiotherapy;
 Prolapse beyond introitus;
 Pregnant or planning pregnancy;
 Recurrent urinary tract infection (UTI) where a
significant pathology has not been excluded;
 Inability to give an informed consent.
Who will take informed consent? {26a}
Members of the local research team trained in good
clinical practice will obtain signed consent forms from
the study participants in all centres. We will check, sign
and date with the date of receipt consent forms that are
returned by post. No study-specific activities will take
place before consent is given.
Additional consent provisions for collection and use of
participant data and biological specimens {26b}
The patient information leaflet (PIL) refers to further
embedded qualitative research within the FUTURE
study. The participants will indicate on the study
consent form if they accept /or not to be contacted by
the qualitative research team for the qualitative study.
The qualitative researcher will take verbal consent for
the qualitative interviews when the interview is
conducted. In addition, the PIL and consent form refer
to the possibility of, and seek the participants’ consent
to, being contacted for longer-term follow-up of the FU-
TURE study to further assess the clinical and cost-
effectiveness outcomes.
Interventions
Explanation for the choice of comparators {6b}
Urodynamics has become standard clinical care without
solid evidence to support its routine or selective use, as
highlighted by the NICE guideline CG171 [11];
therefore, a superiority type design was adopted to
provide the first randomised trial evidence to confirm or
refute the clinical and cost-effectiveness of urodynamics
over comprehensive clinical assessment only.
Intervention description {11a}
We are comparing “urodynamics and comprehensive
clinical assessment” versus “comprehensive clinical
assessment only”. The urodynamics and comprehensive
clinical assessment arm refers to the comprehensive
invasive and non-invasive assessment of women with
urinary symptoms and includes:
 Cystometry
 Free uroflowmetry ± pressure flow studies ± bladder
scan.
 Detailed medical history (assessment of urinary
symptoms (storage, filling and incontinence
symptoms and the most bothersome urinary
symptoms), previous investigations and/or
treatments (conservative, pharmacological and or
surgical) for UI and OAB and past medical or
surgical history of relevance)
 Clinical examination including assessment for stress
urinary incontinence, pelvic organ prolapse and
pelvic masses and other pelvic pathology
 Bladder diary for 3 days to assess daytime frequency,
nocturia, urgency and UUI episodes (N.B. A
minimum of 24 h completed diary will be accepted
as a valid diary. Diary completed at a previous clinic
visit within last 3 months will be accepted)
The comprehensive clinical assessment only arm
includes a detailed medical history, clinical examination,
bladder diary (as outlined above) and post-voiding re-
sidual urine volume using ultrasound bladder scanning.
Some units may also perform non-invasive free
uroflowmetry.
Treatment pathways following intervention
In the urodynamics plus comprehensive clinical
assessment arm the treatment pathway is guided by the
urodynamics diagnosis and is in line with the NICE
guideline (CG171; See Additional file 1 Treatment
Pathway A). The latter recommends BoNT-A 200 units
as the first treatment; however since its publication, fur-
ther evidence confirmed the efficacy of BoNT-A treat-
ment at the lower dose of 100 units with less adverse
events [35] and it has since been licensed in that dose.
Note: Subsequent NG123 also recommended initial
treatment with 100 units [13].
NICE CG171 also recommends offering SNM
treatment for patients who are unable or unwilling to
perform CISC or following unsuccessful BoNT-A
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treatment pending MDT discussion [11]. However, in
view of the lack of robust evidence on the best sequence
of treatments in women with refractory OAB, partici-
pants in both arms of the FUTURE study can be offered
either BoNT-A (100 units) or the SNM test; the decision
will be discussed in the local MDT or as per local stand-
ard best practice. This approach will vary between units
depending on their local clinical practice and the avail-
ability of treatments. Participants with other diagnoses
on urodynamics would be offered the appropriate
treatments.
Depending on the clinical outcome of treatment, we
will offer participants with persistent or de novo
symptoms urodynamic tests and treatment accordingly
or further/ repeat treatment according to comprehensive
clinical assessment only.
In the comprehensive clinical assessment only arm,
the treatment pathway is guided by the clinical diagnosis
and non-invasive tests (See Additional file 1 Treatment
Pathways B). Considering the evidence above, we will
offer participants with clinically diagnosed refractory
OAB or urgency predominant MUI either BoNT-A (100
units) or SNM test. We will discuss the decision in the
local MDT or as per local standard best practice. This
approach will vary between units depending on their
local clinical practice and the availability of treatments.
We will offer participants with other clinical diagnoses
(such as overflow incontinence or SUI predominant
MUI) and other appropriate treatments such as CISC,
SUI surgery or other medical/conservative treatments as
per local standard best practice.
Depending on the clinical outcome of initial
treatment, we will offer participants with persistent or
de novo symptoms urodynamics and treatment
accordingly or may consider repeat/further treatment
according to comprehensive clinical assessment only
(e.g. we may offer patients with persistent OAB
symptoms following treatment with 100 units of BoNT-
A treatment the option of repeat BoNT-A treatment).
Deviation from the treatment pathways may occur
depending on the local clinical practice and the
availability of treatments in the participating units.
However, the Chief Investigator (CI) or delegate will
assess patterns of deviations.
Intervention data to be collected
We will collect intervention data on case report forms
(CRFs). For both arms, this includes data from the
detailed medical history, clinical examination and 3-day
bladder diary, as well as a clinical diagnosis (OAB versus
MUI).
For the urodynamics plus comprehensive clinical
assessment arm, we will also collect data from the
urodynamics test, including urodynamics diagnosis (DO/
MUI/USI/others), voiding assessment on free
uroflowmetry (voided volume, post-voiding residual
urine volume, voiding pattern and maximum and aver-
age flow rate), voiding assessment on pressure flow stud-
ies (if performed) and maximum urethral closure
pressure on urethral pressure profile (if performed).
For the comprehensive clinical assessment arm, we
will collect data on the post-voiding residual urine vol-
ume using ultrasound bladder scanning (and/or non-
invasive free uroflowmetry if performed).
Criteria for discontinuing or modifying allocated
interventions {11b}
There are no special criteria for discontinuing or
modifying allocated interventions. However, in both
study arms, we will offer participants evidence-based
treatments for refractory OAB according to their
diagnosis and as per the defined treatment pathways
which were developed in line with the NICE guideline
CG171 [11].
Strategies to improve adherence to interventions {11c}
To be assured of good quality measurements and
accurate urodynamics data recording, we have developed
a “FUTURE study Guide for Urodynamics Best Practice”
(Additional file 2) in conformity with the 2016
International Continence Society (ICS) Good
Urodynamics Practices [36].
We have developed clear guidance for urodynamic
trace marking to standardise the points used for data in
each study and make central reading/audit of traces
more reliable.
Prior to performing the first randomised urodynamics
test within the FUTURE Study, collaborating units are
required to
 Undertake urodynamics machine calibration checks
for measurements, and
 Submit two anonymous urodynamics traces with
their reports for central reading and review by a
panel of experts within the FUTURE study team.
Feedback is given to centres for any improvement
steps needed.
During the course of the study:
 Collaborating units will submit copies of
urodynamics traces/reports for all participants that
are randomised to the urodynamics arm for
archiving as study data.
 Random central check of traces/reports will be
undertaken after ten traces/reports are submitted
per unit (five for low recruiting units) by the panel
above for quality assurance. If required, one to one
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feedback will be provided and closer monitoring
(random central checks after five traces/reports)
undertaken (Additional file 2).
Web-based training on best urodynamics practice is
available for collaborating units. An expert clinical
engineer (co-investigator) provides one to one support
for collaborating units if/when required.
Relevant concomitant care permitted or prohibited
during the trial {11d}
Usual care for participants continues throughout the
trial. No relevant concomitant care is prohibited.
Provisions for post-trial care {30}
Standard care is provided within the UK National
Health Service.
Outcomes {12}
The primary outcome measure is participant-reported
success at 15 months post-randomisation (approximately
12 months post-treatment) as measured by the PGI-I.
The PGI-I is a validated single item questionnaire de-
signed to assess the participant’s impression of changes
in her urinary symptoms. The PGI-I asks the participant
to best describe her urinary symptoms, compared with
how they were before the study intervention, on a 7-
point scale scored as: (1) “very much improved,” (2)
“much improved,” (3) “improved,” (4) “same,” (5)
“worse,” (6) “much worse,” or (7) “very much worse.
“Success” is defined as responses of “very much im-
proved” or “much improved”; this will capture whether
the women are satisfied with their treatment.
The primary economic outcome is the incremental
cost per QALY gained of urodynamics and
comprehensive clinical assessment compared to
comprehensive clinical assessment only, modelled over
the lifetime of the patients.
Secondary outcome measures are as follows:
○ A less strict definition of success at 15 months
derived from the PGI-I where success is defined as a re-
sponse of “very much improved”, “much improved”, or
“improved”.
○ Proportion of women receiving invasive treatment
at 6 and 15 months post-randomisation.
○ Participant-reported outcomes at 3, 6 and 15
months post-randomisation including:
▪ OAB symptoms measured by the International
Consultation on Incontinence Questionnaire
Overactive Bladder (ICIQ-OAB) and the Urgency
Perception Scale (UPS);
▪ Urgency and UUI episodes measured using the
bladder diary;
▪ Other urinary symptoms measured using the 3
domains of the International Consultation on
Incontinence Questionnaire Female Lower Urinary
Tract Symptoms (ICIQ-FLUTS; filling, voiding and
incontinence) and the bladder diary;
▪ Generic health-related QoL status measured using
general (EQ-5D-5L) and condition specific (Inter-
national Consultation on Incontinence Questionnaire
Lower Urinary Tract Symptoms Quality of Life; ICIQ-
LUTSqol) QoL assessment tools.
○ Adverse events:
▪ All serious adverse events;
▪ UTI requiring antibiotic treatment;
▪ For subsequent treatments:
○ BoNT-A treatment: urinary retention requiring
clinical intervention (e.g. catheterisation); CISC.
○ SNM: infection of the SNM lead; lead migration,
revision of surgery; wound infection.
○ SUI surgery: Bladder injury; intra operative
bleeding requiring return to theatre; post-operative
wound infection; nerve injury; tape exposure/extru-
sion into vagina/lower urinary tract; tape excision/
division; tape infection; new onset and related pelvic
pain; urinary retention requiring intervention (e.g.
catheterisation); CISC; others.
○ Qualitative study outcomes:
▪ Participants’ attitudes to invasive testing and expected
outcomes (prior to randomisation or knowing their
allocated study group);
▪ Participants’ attitudes to potential treatment options
(prior to randomisation or knowing their allocated
study group);
▪ Participants’ experience of urodynamics and opinions
regarding treatment outcome to include evaluation of
treatment satisfaction or desire for further treatment (3
to 6 months post-treatment);
▪ Surgeon attitudes to the influence of urodynamics on
decision-making (at start of the study and 6 to12
months after starting recruitment at their sites).
○ Secondary economic outcomes include:
▪ Incremental cost per QALY gained of urodynamics
and comprehensive clinical assessment compared to
comprehensive clinical assessment only up to 15
months;
▪ Incremental cost per QALY gained of BoNT-A vs
SNM as the initial treatment for refractory OAB over
the lifetime of patients;
▪ Incremental cost per QALY gained of SNM test and
BoNT-A treatment according to clinical assessment
only compared to treatment guided by urodynamics
over the lifetime of patients;
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▪ Expected value of perfect information and associated
partial values over the lifetime of patients.
Participant timeline {13}
See Fig. 1 for the participants’ timelines through the
trial.
Sample size {14}
A survey of the collaborating units showed that in
clinical practice, the majority of women with refractory
OAB are initiated on BoNT-A treatment (60–70%) com-
pared to SNM (15–20%) or other/no treatments (10–
25%). In addition, Rovner et al. and Chapple et al. both
showed a success rate of around 60% in women with re-
fractory OAB without the urodynamics diagnosis of DO
[14, 16]. These two studies defined success differently:
Chapple et al. assessed patient-reported success at 12
weeks following injection of 100 units BoNT-A and de-
fined success as greatly improved or improved [16]; Rov-
ner et al. used a dose of 300 units and defined success as
no UUI episodes recorded in a 7-day diary recorded at
12 weeks post-treatment [14].
We have also established a consensus amongst
clinicians and patient and public involvement groups
(PPI) that for urodynamics to be worthwhile, it will need
to demonstrate a minimum of 10% superiority over
comprehensive clinical assessment only. For 90% power
and a 5% level of significance, 986 participants (493/
group) are needed using a chi-squared test with continu-
ity correction [37, 38], rising to 1096 (or 548/group) to
allow for 10% attrition at 15 months post-randomisation.
Recruitment {15
Local research teams will identify all potentially eligible
women at outpatient clinics or waiting lists for
urodynamics/outpatient clinics in each recruiting centre.
We may also use participant identification centres
(PICs) to identify potential patients. Posters within
appropriate clinics will provide information about the
study. Local procedures at the participating hospitals
will vary and the timing and mode of approach to
women and the consent process may accommodate both
the specific circumstances at each site and the needs of
the women.
We will give or send each eligible woman a PIL
describing the FUTURE study and they will have the
opportunity to discuss the study with her consultant.
Women may also receive their local hospital PIL
regarding the urodynamics investigation. Women will
have the opportunity to discuss all aspects of the
proposed research with the local clinical team
(consultant/staff at clinics), the research nurse (RN), and
if appropriate, general practitioner, family and friends.
Women may make a decision to participate during an
initial consultation with their consultant or during a
subsequent visit to hospital (e.g. a clinic appointment) or
alternatively at home.
The local RN may telephone eligible women to discuss
any queries and arrange a baseline assessment visit. For
women who decide to participate, we will send or give
them the study documents (consent form and baseline
questionnaires) to complete at home. They can either
send their completed documents (consent form and
baseline questionnaire) through the post to the local
team at their treating hospital or bring it with them if
they are returning to hospital for another consultation
or assessment.
We will keep a log of all potentially eligible patients
assessed in order to document the reasons for non-
inclusion in the study (e.g. reason they were ineligible or
declined to participate) to inform the Consolidated Stan-
dards of Reporting Trials (CONSORT) diagram. We will
record brief details of potentially eligible patients in the
screening logs at each site (these are an aid to monitor-
ing potential participant inclusion). We will assign all
women who enter the study a unique study number.
We will send participants who also consent to the
qualitative research a dedicated PIL for the qualitative
study interviews. This will be followed by an email and/
or phone call from a qualitative team researcher to
answer any of the participants’ queries.
Assignment of interventions: allocation
Sequence generation {16a}
Eligible and consenting participants will be randomised
after completing the baseline assessment to either
“urodynamics and comprehensive clinical assessment” or
“comprehensive clinical assessment only” using the
randomisation application at the trial office at the
Centre for Healthcare Randomised Trials (CHaRT),
University of Aberdeen.
This randomisation application is available 24 h a day,
7 days a week as a web-based application. The random-
isation uses stratified random permuted blocks with (a)
centre, and (b) diagnosis of OAB versus Mixed Urinary
Incontinence used as stratum. In addition, a random
component is used in the minimisation algorithm to en-
sure concealment of the allocation.
Concealment mechanism {16b}
The web-based randomisation system ensures allocation
concealment.
Implementation {16c}
The Principal Investigator (PI) at site, or member of the
local research team (with delegated authority), will
access the web-based system. They will enter
Abdel-fattah et al. Trials          (2021) 22:745 Page 10 of 18
stratification characteristics into the web-based system,
which returns the allocation status. We will inform par-
ticipants of their allocated pathway following randomisa-
tion. If the participants are not present at the time of
randomisation, the research team will contact the par-
ticipant to inform them of the allocated pathway after
randomisation. We will inform participants who have
consented to take part in the embedded qualitative study
of their allocated pathway after their initial qualitative
interview.
Assignment of interventions: Blinding
Who will be blinded {17a}
Participants, clinical staff or the central trial team
cannot be blinded to the allocated procedure because of
the nature of the interventions.
Procedure for unblinding if needed {17b}
There are no requirements for emergency unblinding
procedures.
Data collection and management
Plans for assessment and collection of outcomes {18a}
We will collect data at baseline and at 3, 6 and 15
months post-randomisation (see Table 1). We will also
collect intervention data for each participant.
We will collect qualitative data via face to face
participants’ interviews where possible, with telephone
interviews included for remote study sites, and carried
out by an experienced qualitative researcher.
Plans to promote participant retention and complete
follow-up {18b}
We offer and use all methods of delivery and collection
of questionnaires and reminders including use of
research teams for time points associated with
hospitalisation, post, e-mail, web-based and SMS text,
taking into account each participant’s stated preferred
means of receiving and completing the measures (re-
corded on the participant contact preference form).
We will send up to three reminders to participants by
post, email, phone or text message, taking into account
any preferences they may have for mode of
communication.
We will send a small token of appreciation (gift
voucher(s) of modest value up to £15) to participants on
receiving their completed follow-up questionnaires, un-
less they opt out on the study consent form.
Data management {19}
The local research team enters locally collected data in
the centres. Staff in the trial office will work closely with
local research teams to ensure the data are as complete
and accurate as possible.
Follow-up questionnaires to participants are sent from
and returned to the trial office in Aberdeen. Extensive
Table 1 Source and timing of outcome measures to be assessed
Outcome measure Source Timing
Baselinea Post-randomisation (months)
3 6 15
Treatment success PGI-I PQ ✓ ✓ ✓
Generic health status PQ ✓ ✓ ✓ ✓
EQ-5D-5L
Condition specific quality of life PQ ✓ ✓ ✓
ICIQ-LUTSqol
Urinary symptoms PQ ✓ ✓ ✓ ✓
ICIQ-OAB
ICIQ-FLUTS
UPS: Urgency Perception Scale
Urgency and urgency urinary incontinence episodes on (3-day bladder diary) PQ ✓ ✓ ✓
Bladder scan CRF ✓
Interventions received CRF, PQ ✓ ✓ ✓
Adverse events CRF, PQ ✓ ✓ ✓
NHS primary and secondary healthcare use CRF, PQ ✓ ✓ ✓
Participant resource use PQ ✓ ✓ ✓
CRF case report form, PQ participant-completed questionnaire
aBaseline is after informed consent has been given but prior to randomisation
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range and consistency checks are designed to further
enhance the quality of the data.
Confidentiality {27}
Data collected during the course of the research is kept
strictly confidential and accessed only by members of
the trial team and may be looked at by individuals from
the Sponsor organisation or NHS site for the purposes
of monitoring and audit.
Participants are allocated a unique study number.
Participant’s details are stored on a secure database
under the guidelines of the 1998 Data Protection Act.
To comply with the 5th Principle of the Data Protection
Act 1998, personal data will not be kept for longer than
is required for the purpose for which it has been
acquired. The CHaRT senior IT manager (in
collaboration with the CI) manages access rights to the
data set. We anticipate that anonymised trial data may
be shared with other researchers to enable international
prospective meta-analyses.
Plans for collection, laboratory evaluation and storage of
biological specimens for genetic or molecular analysis in
this trial/future use {33}
There are no plans for the collection, laboratory
evaluation or storage of biological specimens for genetic
or molecular analysis in this trial.
Statistical methods
Statistical methods for primary and secondary outcomes
{20a}
We will compare primary and secondary outcomes
using generalised linear models, with adjustment for the
minimisation covariates (centre and diagnosis of OAB
versus MUI). We will use sensitivity analyses to explore
additional adjustment of healthcare professional effects
which arise from a better diagnosis being made due to
the use of urodynamics. This is similar to adjusting for
surgeon effects when there is more than one surgeon
within a centre.
The primary outcome is participant-reported success
as measured by the PGI-I at 15 months post-
randomisation (approximately 12 months post-
treatment). For the primary analysis, the PGI-I responses
will be dichotomised to “success” defined as “very much
improved” or “much improved” as this is felt to be the
best categorisation of whether the women are satisfied
with their treatments and interventions. We will use a
repeated measures mixed effects logistic regression, in-
cluding the 6-month measurement to increase the power
to estimate the treatment effect at 15 months post-
randomisation.
We will analyse secondary outcomes using the
appropriate linear model. For example, we will analyse
the less strict definition of success using a repeated
measures mixed effects logistic regression in the same
way as the primary outcome will be analysed. We will
also analyse the proportion of women receiving invasive
treatment using a logistic regression. We will analyse
continuous outcomes such as the ICIQ-FLUTS scores
and quality of life scores and the EQ-5D-5L using a re-
peated measures mixed effects linear regression.
We will make available the statistical analysis plan and
the health economy analysis plan as a separate
publication(s).
Quality-adjusted life years
We will estimate QALYs using the EQ-5D-5L tariff that
is recommended by NICE at the time of the analysis; this
is currently the van Hout “cross-walk” tariff [39]. We
will estimate QALYs using linear interpolation between
time points. We will undertake exploratory analysis to
assess the QALY loss related to urodynamics (e.g. anx-
iety and discomfort) by estimating the degree to which
EQ-5D-5L values at 3 months post-randomisation are af-
fected by time since urodynamic testing. If a robust esti-
mate of QALY loss is produced, we will examine the
impact of its incorporation into the cost-effectiveness
analysis using a sensitivity analysis.
Within trial cost-effectiveness analysis
The within trial analysis will follow the best practice
guidelines [40]. The analysis will calculate total costs
and QALYs for each patient and estimate the
incremental costs and QALYs using a seemingly
unrelated regression model with baseline covariates
including age and baseline EQ-5D-5L score and missing
data imputed using multiple imputation [41, 42].
We will base the cost-effectiveness acceptability curves
on the adjusted and imputed analysis described above.
We will undertake deterministic sensitivity analyses to
look at three sources of methodological uncertainty; so-
cietal perspective, the EQ-5D-5L tariff and any QALY
loss associated with urodynamics identified in the ex-
ploratory analysis described above. Undertaking a sensi-
tivity analysis with the EQ-5D-5L tariff is required as
alternative tariffs are available; the current recom-
mended tariff is the van Hout “cross-walk” tariff [43]
Patient lifetime cost-effectiveness analysis
The primary analysis is model based. Such an approach
is considered superior to trial-based analyses as it can be
designed to better fit the research question and incorp-
orate other relevant sources of data [44]. In this particu-
lar situation, the model can incorporate the longer-term
costs and consequence of using urodynamics which can-
not be observed in the trial. However, the first 15
months of the model will be based on the trial results.
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The structure of the model beyond 15months will be
based on a pre-existing model [18]. A key improvement
over this model is the use of more appropriate utilities
taken from the trial. In addition, we will undertake tar-
geted literature searches to assess whether any relevant
new studies have been published for the other
parameters.
In line with the Rachaneni model [18], exploratory
analyses examine whether targeted urodynamics for a
subgroup of patients has the potential to be cost-
effective. In addition to Rachaneni, we will undertake
two exploratory analyses:
 A non-randomised comparison of the cost-
effectiveness of different sequence of treatments (i.e.
initiated on BoNT-A vs SNM).
 A non-randomised comparison of the cost-
effectiveness of SNM according to clinical assess-
ment only compared to treatment guided by
urodynamics.
These two comparisons take account of the lack of
randomisation using methods consistent with those of
the analogous clinical analyses.
We will also undertake a probabilistic sensitivity
analysis on the modelled results and its associated
incremental cost-effectiveness ratio, cost-effectiveness
plane and cost-effectiveness acceptability curves gener-
ated. We will undertake a value of information analysis
using SAVI (http://savi.shef.ac.uk/SAVI/). The partial
values are used to identify those parameters where there
is greatest value in resolving outstanding uncertainty.
We will undertake a deterministic sensitivity analyses to
look at the three sources of methodological uncertainty;
societal perspective, the EQ-5D-5L tariff and the length
of disutility associated with urodynamics.
Qualitative interviews
A standardised approach will be employed in accordance
with published qualitative research methods [45–49].
Interviews are semi-structured and follow a topic
guide informed by literature review and discussion be-
tween study researchers and encourage participants to
discuss their perspectives with regard to the qualitative
study aims. Interviews are audio recorded, transcribed
verbatim (including descriptions of non-verbal factors
where appropriate) and uploaded onto a qualitative soft-
ware package (QSR Nvivo 10) to aid data management.
The qualitative researcher will conduct the analyses ac-
cording to principles of thematic content analysis.
We will use theoretical purposive (non-probability)
sampling to ensure the diverse characteristics of the
population are sampled (e.g. participants varying in age,
relevant clinical history (MUI vs OAB), investigations
received (urodynamics and comprehensive clinical
assessment versus comprehensive clinical assessment
only), and treatments received (SNM vs. BoNT to
include day case vs. local anaesthetic procedures).
Sampling and analyses continue in iterative cycles until
data saturation is achieved. It is anticipated a minimum
of thirty to forty patient interviews will be undertaken to
effectively capture the opinions of those in both arms of
randomisation, the numerous potential treatments and
treatment considered successful and failed.
Approximately ten to fifteen clinician interviews are
proposed to explore the clinical aspects of urodynamics
with regard to clinical decision-making.
Interim analyses {21b}
There will be no interim analyses.
Methods for additional analyses (e.g. subgroup analyses)
{20b}
We will perform a secondary supporting analysis of the
primary outcome using ordinal logistic regression on the
7-point PGI-I scale. This will use a generalised ordered
logit model with the partial proportional odds model
(for example, as implemented in “gologit2” in Stata) to
relax this restrictive assumption of the full proportional
odds model. We will also include a suitably defined per
protocol analysis as a secondary supporting analysis.
We will compare the outcomes in pre-specified sub-
groups of participants with OAB vs MUI. In addition,
we will explore, in a non-randomised analysis, the
following:
1. Clinical and cost-effectiveness of the different treat-
ment pathways of those initiated on BoNT-A treat-
ment vs those initiated on SNM treatment.
2. Clinical and cost-effectiveness of SNM treatment
according to clinical assessment only compared to
treatment guided by urodynamics.
3. Clinical and cost-effectiveness of BoNT-A treat-
ment according to clinical assessment only com-
pared to treatment guided by urodynamics
Methods in analysis to handle protocol non-adherence
and any statistical methods to handle missing data {20c}
Analysis will be by intention-to-treat. We will assess
how robust all findings are to any missing data (antici-
pated to be no more than 10% for the primary outcome)
using multiple imputation approaches under an assump-
tion of missing at random. We will consider non-
ignorable missing data mechanisms if the patterns of
missing data across the two randomised groups suggest
this is appropriate.
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Plans to give access to the full protocol, participant-level
data and statistical code {31c}
The full protocol is available on the funder’s website
(https://www.journalslibrary.nihr.ac.uk/programmes/
hta/1515005/#/). Non-identifiable participant-level data
may be available on request to the Chief Investigator
( C I ) , P r o f e s s o r Moh amed Abd e l - f a t t a h (m .
abdelfattah@abdn.ac.uk)
Oversight and monitoring
Composition of the coordinating centre and trial steering
committee {5d}
The Trial Office is in CHaRT based within the Health
Services Research Unit, University of Aberdeen and
provides day to day support for the clinical centres. The
Trial Manager takes responsibility for the day to day
transaction of trial activities, for example approvals, site
set-up and training, oversight of recruitment and follow-
up rates. The Data Coordinator provides clerical support
to the trial, including organising all aspects of the ques-
tionnaires (mailing, tracking and entering returned data
using the trial web data entry portal).
The FUTURE Trial Office Team (CI, trial manager,
data coordinator, statistician) meets formally,
approximately fortnightly during the course of the
study to ensure smooth running and trouble-shooting,
but more frequently during the set-up phase as
required.
The trial is supervised by its Project Management
Group (PMG). The group consists of grant holders
(clinicians, statisticians, health economists and
qualitative researchers) and representatives from the
Trial Office. Observers are invited to attend at the
discretion of the PMG. The PMG meets
approximately every 2 months in the first and last 6
months of the trial and approximately every 3 months
in-between.
The PMG has the expertise to cover the clinical,
methodological and management aspects of the
FUTURE study.
Any modification to the project is normally discussed
by the PMG, and when relevant by the Trial Steering
Committee (TSC) and is approved by the Sponsors and
funder before application to the Research Ethics
Committee (REC) and Research and Development
(R&D). An exception to the above is in the case where
an immediate implementation of safety measures is
required; the Sponsor is then notified as soon as
possible.
A TSC oversees the conduct and progress of the
FUTURE study. The TSC meets annually and includes
an independent chair, clinical and methodological
expertise and a lay representative.
Composition of the data monitoring committee, its role
and reporting structure {21a}
An independent Data Monitoring Committee (DMC)
oversees the safety of participants in the FUTURE study.
The DMC Charter documents the terms of reference of
the DMC and the names and contact details. This is
filed in the Trial Master File. The committee meets
every 6 to 12 months to monitor the study data and
make recommendations as to any modifications that are
required to be made to the protocol or the termination
of all or part of the study. The study has adopted the
DAMOCLES Charter for DMCs [50].
Adverse event reporting and harms {22}
In FUTURE, we will only record adverse events (AEs)
and serious adverse events (SAEs) related to the study
interventions. A serious adverse event is defined as any
AE that results in death, is life threatening (i.e. the
subject was at risk of death at the time of the event; it
does not refer to an event which hypothetically might
have caused death if it were more severe), results in
persistent or significant disability or incapacity, requires
hospitalisation or prolongation of existing hospitalisation
or is otherwise considered medically significant by the
investigator.
All AEs and SAEs meeting the criteria for recording
within the trial are recorded from the time a participant
consents to join the trial until the end of their follow-up
period. Every follow-up visit and questionnaire will
inquire on expected AEs/SAEs. In addition, we will use
open ended and non-leading verbal questioning of the
participant to enquire about AE/SAE occurrence or re-
admission to hospital and any further treatment
received.
Depending on severity, when an AE/SAE meeting the
criteria for recording within the FUTURE Study occurs,
it is the responsibility of the local PI (or delegate) to
review appropriate documentation (e.g. hospital notes,
laboratory and diagnostic reports) related to the event.
The PI or delegate should then record all relevant
information in the CRF (and on the SAE form if
required).
PI or delegates are responsible for notifying the trial
office of any SAEs that require to be recorded in line
with the FUTURE study protocol. If an SAE is recorded
on a participant questionnaire, the Trial office liaises
with the relevant study site to obtain further
information.
When an SAE form is uploaded onto the trial website,
the Trial Manager is automatically notified. If, in the
opinion of the local PI and/or the CI, the event is
confirmed as being serious and related and unexpected,
the CI or Trial Manager notifies the sponsor within 24 h
of receiving the signed SAE notification. The sponsor
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provides an assessment of the SAE. A Sponsor cannot
downgrade an assessment from the PI or CI. Any
disparity is resolved by further discussion between these
parties.
The CI or delegate reports any related and unexpected
SAEs to the REC within 15 days of the CI becoming
aware of it.
Frequency and plans for auditing trial conduct {23}
The CI/ PMG ensures, through the TSC and Sponsor,
that adequate systems are in place for monitoring the
quality of the trial (compliance with appropriate
governance) and appropriate expedited and routine
reports, to a level appropriate to the risk assessment of
the trial. CHaRT’s Standard Operating Procedures are
followed.
The approach to, and extent of, monitoring are
specified in a trial monitoring plan and is appropriate to
the risk assessment of the trial. PIs and their host Trusts
are required to permit trial related monitoring and
audits to take place by the Sponsor and/ or regulatory
representatives providing direct access to source data
and documents as requested.
Plans for communicating important protocol
amendments to relevant parties (e.g. trial participants,
ethical committees) {25}
Any amendments to the project are approved by the
Sponsors and funder before application to REC and
R&D unless in the case of immediate safety measures
being required/ implemented when the Sponsor is
notified as soon as possible. Any deviations from the
Protocol will be fully documented.
Dissemination plans {31a}
We will develop a publication and dissemination plan to
include conference presentation(s) and journal
publication(s).
The findings of the trial will be disseminated
nationally through the UK Continence Society (UKCS),
British Society for Urogynaecology (BSUG) and British
Association of Urological Surgeons (BAUS) and
internationally though the European Association of
Urology (EAU) and ICS.
BAUS, UKCS and BSUG are the UK specialist bodies
with the responsibility of guiding clinical practice,
policies, research priorities, governance and training in
matters related to UI in women. UKCS provide
urodynamics guidance and unit accreditation in the UK.
They are well placed to implement the findings by
influencing NHS policy and dissemination of evidence-
based clinical practice to its members. The results of the
trial will be included in updates of NICE and EAU
guidelines, which directly influence practice in the UK
and beyond.
Our dissemination plans include a Health Technology
Assessment (HTA) monograph; presentations at the
UKCS, BSUG, BAUS, EAU, ICS annual scientific
meetings; publications in high-impact open access peer-
reviewed journals; presentations at health economic and
health services research meetings; and development of
plain English language summaries of our main findings
for patient organisations and communities.
We plan to use our PPI partners, Bladder Health UK
(Charity Reg No: 1149973A), to ensure this information
meets the needs of users, and we shall share our findings
with all FUTURE participants. In addition, summaries
will be published in health-related media such as Reuters
Medical, Uro-today and Nature. We will use social
media such as Twitter and Facebook to inform the OAB
user groups with a summary of the study results.
Discussion
The FUTURE trial is a large, pragmatic, multi-centre,
superiority randomised controlled trial to determine the
effectiveness and cost-effectiveness of routine uro-
dynamics plus comprehensive clinical assessment versus
comprehensive clinical assessment only in the manage-
ment of women with refractory OAB symptoms.
The trial team established collaboration with the
largest relevant patient support groups in the UK to
provide insights from the patient’s perspective. The
Bowel and Bladder Foundation advised on the treatment
pathways, proposed assessment tools and outcome
measures at time of study design. Unfortunately, they
later ceased to exist as an independent PPI group.
Bladder Health UK is a grant holder and part of the
PMG providing clear leadership on the patient
perspective and is integral to the development of the
study protocol and all the study documents including
the patient information sheet; letters of invitation/
reminders; participants’ questionnaires and the bladder
diary.
To maximise recruitment into the trial, FUTURE
adopted a hub structure. Each hub has approximately 10
allocated centres and is led by a hub leader and a funded
part time hub coordinator. The hub leader and
coordinator support the trial manager with the set-up of
centres, ensure continuous engagement of PIs and re-
search nurses and promote recruitment within their
hubs.
As with most clinical trials, recruitment and
participant retention are key challenges. The study team
has adopted several strategies to promote recruitment
and retention within FUTURE. These include the
following: the inclusion of Participant Identification
centres (PICs), encouragement of collaborating centres
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to engage both Gynaecology and Urology departments,
and organisation of regional hub meetings at which the
CI and trial manager attend. We have made a
recruitment illustration video which is available on the
study website to aid sites through recruitment. We also
utilise regular site and participant newsletters to sustain
positive engagement with centres and participants.
Finally, we opened more centres than originally planned
(65 vs planned 38 centres)
NICE CG 171 was the relevant guideline at the time of
the FUTURE study planning in 2017. In 2019, NICE
updated their guideline on the management of UI in
women with the publication of NG123. NG123 slightly
amended their recommendation to “consider offering
BoNT-A treatment, following MDT discussion, to
women with refractory OAB in whom DO was not dem-
onstrated on urodynamics” [13]. There were no changes
to the recommendation of routine urodynamics investi-
gations in women with refractory OAB. These changes
did not require any change to the FUTURE study
protocol.
The results of the FUTURE study are expected to
answer the important research question on whether
routine urodynamics investigation in addition to
comprehensive clinical assessment improve patient-
reported outcomes following treatment and is cost-
effective, compared to comprehensive clinical assess-
ment only, in women with refractory OAB symptoms.
The study results will have an impact on all the major
stakeholders involved in the management of refractory
OAB in women. The findings are expected to be incor-
porated into clinical practice guidelines and treatment
recommendations from NICE, UKCS, BSUG and EAU.
For patients and clinicians, the study results are ex-
pected to facilitate and guide treatment decision-making.
The results will also provide cost-effectiveness evidence
for the NHS, which will facilitate decision-making re-
garding the allocation of resources for treatment, and
provision of services.
Trial status
The first participant was recruited in November 2017.
The current protocol version is 10.0, 01/07/2021.
Recruitment was due to complete on 31st May 2020.
However, on instruction by the Trial Sponsor,
recruitment was suspended on 16th March 2020 due to
the COVID-19 outbreak. At this point, 1022 participants
had been randomised. Recruitment restarted in August
2020 and the recruitment end date extended to 31st
January 2021. Please see additional file 3 for further im-
plications of the COVID-19 pandemic.
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